DelveInsight's 2025 pipeline report reveals more than 200 companies developing 220+ therapies for Non-Hodgkin's Lymphoma, demonstrating robust research activity in this therapeutic area.
HUTCHMED achieved net income of $37.7 million in 2024, reaching profitability ahead of schedule with strong oncology products revenue growth of 65% to $271.5 million.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.